Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 15;9(8):e030648.
doi: 10.1136/bmjopen-2019-030648.

Efficacy and safety of the combination of reduced duration prophylaxis followed by immuno-guided prophylaxis to prevent cytomegalovirus disease in lung transplant recipients (CYTOCOR STUDY): an open-label, randomised, non-inferiority clinical trial

Aurora Paez-Vega  1   2 , Sara Cantisan  3   2   4 , José Manuel Vaquero  5 , Elisa Vidal  1   2   4 , Antonio Luque-Pineda  6 , María Ángeles Lobo-Acosta  7 , Ana Belén Pérez  1   8 , Rodrigo Alonso-Moralejo  9 , David Iturbe  10 , Victor Monforte  11   12 , Isabel Otero-Gonzalez  13 , Amparo Pastor  14 , Piedad Ussetti  15 , Julian Torre-Cisneros  1   2   4
Affiliations

Efficacy and safety of the combination of reduced duration prophylaxis followed by immuno-guided prophylaxis to prevent cytomegalovirus disease in lung transplant recipients (CYTOCOR STUDY): an open-label, randomised, non-inferiority clinical trial

Aurora Paez-Vega et al. BMJ Open. .

Abstract

Introduction: Prolonged use of antivirals to prevent the development of cytomegalovirus (CMV) disease in lung transplant patients has been shown to have significant side effects, for which alternatives are being sought to reduce their use. The monitoring of cell immunity against CMV could be an alternative as it has shown to be useful in identifying transplant patients at low risk of infection, who could benefit from shorter prophylaxis. The aim of the CYTOCOR study is to demonstrate that the combination of a reduced prophylaxis strategy with subsequent CMV-specific immunological monitoring would allow CMV infection to be controlled in lung transplant patients as effectively as the usual strategy (prophylaxis followed by pre-emptive therapy), while reducing the side effects of antivirals due to the shorter duration of prophylaxis.

Methods and analysis: Phase III randomised, open, multicentre, parallel, non-inferiority clinical trial to study the efficacy and safety of the combination of a prophylaxis strategy up to month +3 post-transplant followed by immuno-guided prophylaxis using the QuantiFERON-CMV technique up to month +12 post-transplant to prevent CMV disease in CMV-seropositive lung transplant recipients. This strategy will be compared with a combination of a usual prophylaxis strategy up to month +6 post-transplant followed by pre-emptive therapy up to month +12. To study the incidence of CMV disease, patients will be followed up to 18 months post-transplantation. A total of 150 patients are expected to be recruited for the study.

Ethics and public dissemination: The clinical trial has been approved by the Research Ethics Committees and authorised by the Spanish Agency of Medicines and Medical Devices (AEMPS).If the hypothesis of this clinical trial is verified, the dissemination of the results could change clinical practice by increasing knowledge about the safety and efficacy of discontinuing valganciclovir prophylaxis in lung transplant recipients.

Trial registration number: NCT03699254.

Keywords: cytomegalovirus; immuno-guided prophylaxis; lung transplantation.

PubMed Disclaimer

Conflict of interest statement

Competing interests: J.T.C. and S.C. have received an unrestricted research grant from Roche Pharma and Qiagen. They have also received payments from Qiagen for educational activities.

Figures

Figure 1
Figure 1
Flow diagram. CMV,cytomegalovirus; QF-CMV, QuantiFERON-CMV.
Figure 2
Figure 2
Study design. m, month; PCR, polymerase chain reaction.
See this image and copyright information in PMC

References

    1. Torre-Cisneros J, Aguado JM, Caston JJ, et al. . Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. Transplant Rev 2016;30:119–43. 10.1016/j.trre.2016.04.001 - DOI - PubMed
    1. Kotton CN, Kumar D, Caliendo AM, et al. . The transplantation Society international CMV consensus group. The third International consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2018;102:900–31. - PubMed
    1. Egli A, Humar A, Kumar D, et al. . State-Of-The-Art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician. Clin Infect Dis 2012;55:1678–89. 10.1093/cid/cis818 - DOI - PubMed
    1. Manuel O, Husain S, Kumar D, et al. . Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clinical Infectious Diseases 2013;56:817–24. 10.1093/cid/cis993 - DOI - PubMed
    1. Lisboa LF, Kumar D, Wilson LE, et al. . Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation 2012;93:195–200. 10.1097/TP.0b013e31823c1cd4 - DOI - PubMed

Publication types

MeSH terms

Substances

Associated data